August 2004 Volume 11 Issue 3

The Future of Dissolution Testing: USP,Academic, FDA, and Industry Perspectives Dissolution: a Continuing Perspective Roger L.Williams, 1 and Thomas Foster, 2 1 Chair, Council of Experts 2 Chair, Biopharmaceutics Expert Committee United States Pharmacopeia, Rockville,MD Future Directions for Academic Researchin Dissolution Testing Jennifer B. Dressman J.W. Goethe University, Frankfurt am Main,Germany Role of Dissolution Testing: Regulatory Perspectives Vinod P. Shah Office of Pharmaceutical Science Center for Drug Evaluation and Research Food and Drug Administration, Rockville,MD Future Directions for Dissolution Testing in the Pharmaceutical Industry Vivian A. Gray Dissolution Technologies,Hockessin, DE The Development and Validation of a Dissolution Method for Clomipramine Solid Dosage Forms Mehdi Ansari 1,Maryam Kazemipour 2, and Javad Talebnia 1 1 Department of Pharmaceutics, Faculty of Pharmacy, Kerman Medical Sciences University, Kerman, Iran 2 Department of Chemistry, Faculty of Sciences, Kerman Azad University, Kerman, Iran Statistical Properties of the Dissolution Test of the USP Carlos D. Saccone 1, Julio Tessore 1, Silvino A. Olivera 2, and Nora S. Meneces 1 1 University of the Republic of Uruguay, Faculty of Engineering, Industrial Production Department, Montevideo,Uruguay 2 University of the Republic of Uruguay, Faculty of Chemistry, Estrella Campos Department, Montevideo,Uruguay Question & Answer Section Margareth Marques and William Brown United States Pharmacopeia, Rockville,MD